A Phase I/II gene therapy trial for macular atrophy secondary to AMD (NCT03846193) is also ongoing using GT005 (Gyroscope Therapeutics Limited, London, UK), a recombinant non-replicating AAV encoding human complement factor I (CFI). The gene discussed is CFI; the disease is age-related macular degeneration.